Lecanemab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Lecanemab and local guidelines before prescribing.
Anti-amyloid antibody
Mechanism
Anti-amyloid beta monoclonal antibody.
Uses
Early Alzheimer disease (specialist).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
ARIA, infusion reactions, headache.
Interactions
Anticoagulants increase risk.
Contraindications and cautions
Anticoagulation
Monitoring
MRI
Pregnancy and breastfeeding
Not applicable
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
MRI monitoring before doses.
More from the textbook: uses, cautions and other points
- Anti-amyloid antibodies (lecanemab, donanemab) - licensed for early Alzheimer's but not recommended by NICE for NHS use ; risk of ARIA (brain swelling and microbleeds), especially in people with two APOE4 copies or on anticoagulants.
Neurology: Anatomy, Physiology and Pharmacology - Lecanemab / donanemab | MHRA-licensed anti-amyloid antibodies; ARIA risk; not recommended by NICE for NHS use.
Neurology: Dementia and Cognition Disorders (Complete) - NICE technology appraisal guidance on lecanemab and donanemab (2025)
Neurology: Dementia and Cognition Disorders (Complete) - Amyloid antibodies (lecanemab, donanemab) - licensed in the UK for early Alzheimer's but not recommended by NICE for NHS use (modest benefit, ARIA - brain swelling and bleeding - and cost).
Medicine of the older adult: Delirium, dementia and mood in older people - NICE Technology Appraisal: Lecanemab and donanemab for early Alzheimer's disease (not recommended)
Medicine of the older adult: Delirium, dementia and mood in older people - Treatment - treat the underlying cause: chemotherapy (daratumumab-based) ± stem cell transplant (AL), suppress inflammation (AA - anti-TNF, IL-1 or IL-6 blockade, colchicine in FMF), TTR stabilisers or silencers (ATTR), anti-amyloid antibodies in early Alzheimer's (lecanemab, donanemab - MHRA licensed 2024 but not recommended by NICE for …
Pathology: Immunopathology, amyloidosis, genetic and environmental disease